CAB+RPV LA Is Versatile, Preferred in Treatment-Naive Patients

Why It Matters

The data confirm that long‑acting injectables can maintain viral suppression while addressing adherence barriers, reshaping HIV treatment standards for both new and experienced patients.

Key Takeaways

• 85% of ART‑naïve participants switched to CAB+RPV LA
• Month‑11 suppression reached 95% overall
• Switchers achieved 88% viral suppression <50 copies/mL
• OPERA showed 1‑2% virologic failure across viral loads
• Retention above 70% despite dosing delays

Pulse Analysis

Long‑acting HIV therapies are gaining traction as clinicians seek to reduce pill fatigue and improve adherence. Cabotegravir combined with rilpivirine offers a monthly or bimonthly injectable that matches the efficacy of daily oral regimens while simplifying dosing logistics. This shift aligns with broader market trends favoring patient‑driven care models and could expand market share for manufacturers that can deliver reliable, low‑frequency formulations.

The VOLITION study provides the first robust evidence that treatment‑naïve patients can safely transition early from a potent oral backbone (DTG/3TC) to CAB+RPV LA without compromising viral control. With 85% electing the switch and 88% of those achieving HIV‑RNA < 50 copies/mL at month 11, the trial underscores the importance of offering flexible options at the point of viral suppression. High satisfaction scores and motivations centered on convenience suggest that injectable therapy meets a genuine unmet need for patients who travel or struggle with daily pill adherence.

Real‑world data from the OPERA cohort extend these findings to a larger, treatment‑experienced population. Despite baseline viral loads above or below the 50‑copy threshold, suppression rates remained high (95% vs 87%) and virologic failure stayed low (1‑2%). Retention rates above 70%—even with short and long injection delays—demonstrate the regimen’s durability in routine practice. Collectively, these results position CAB+RPV LA as a preferred long‑acting option, likely accelerating its adoption across diverse care settings and influencing future HIV treatment guidelines.